Welcome to Drug and Alcohol Treatment
| ||
Drug Treatment European Article
This is a selection made from among articles on Drug Treatment European. For a permanent link to this article, or to bookmark it for future reading, click here.
Drug Testing In Schools
from: Drug Testing Programs in Schools are measures that teachers and administrators of a school put into place in order to discourage drug use by students. School districts saw widespread implementation of comprehensive Drug and Alcohol policies starting in the mid-1980s. Although small town school districts have generally been slower to adopt these measures, teenage drug use has not spared rural and suburban schools either.
There are many pros and cons in the school drug testing programs. Some say that the main purpose of school drug testing is not to catch kids using drugs, but to prevent them from ever using drugs, illegal or not. Once teenagers are using drugs it is much harder for them to break their addiction. If by testing the athletes or other school leaders, we can get them to say no to drugs, it will be easier for other kids to say no.
Reasons for Student Drug Testing:
· Testing gives students a chance to say "No to Drugs" when approached to use drugs.
· Student drug testing is important because children become addicted more rapidly than adults and their recovery is less likely.
· Students have a right to safe and drug-free learning environments. School administrators need reasonable tools to stop drug users and drug dealers from ruining school for everyone.
· Testing gives parents an opportunity for intervention and treatment. Parents have the right to send their kids to drug-free schools. The thought of sending their kids to a school where drugs are rampant scares parents. Drug testing helps keep our kids safe.
· The intent of this program is not to punish students. The goal is for the drug user to straighten his or her life out. The schools use drug testing as a tool to deter drug use and help students to get drug education and/or counseling. The results are not turned over to law enforcement.
The Supreme Court ruled in 1995 (in Vernonia v. Acton) that schools could randomly test student athletes who are not suspected of drug use. The Court also stated that as school athletes routinely face mandatory physicals and other similar invasions of privacy, they have lower expectations of privacy than the average student. The Court specified that its decision should not be seen as a justification for further expansion of drug testing programs. In 2002 (the Board of Education of Independent School District No. 92 of Pottawatomie County v. Earls) it was ruled in Supreme Court that all students who participate in voluntary activities, like cheerleading, band, or debate, could be subjected to random tests as well.
It's not a trust issue it's a health and safety issue. We are talking about kids here. Schools that have drug testing programs makes atmosphere become more positive. In addition, drug test results are used for counseling purposes and are not turned over to law enforcement.
About Author
DrugAlcoholTest.com is an online store offering drug test and drug screening products in several formats including blood, urine and oral drug test kits. DrugAlchoholTest.com offers FDA-approved urine drug testing kits as well as DOT-approved alcohol testing products. These drug testing kits can be used discreetly for at home drug test or for random employee drug testing. Some of the popular products are marijuana drug test, breathalyzer and saliva drug test products. A professionally management company that is a responsible, and socially aware company with a mission to make ours a healthier and better society.
Source: ArticleTrader.com
Drug Treatment European Specific links
Drug Treatment European News
Pfizer says EU recommends approval of Inlyta - CBS News
Pfizer says EU recommends approval of Inlyta CBS News NEW YORK — Pfizer Inc. said Friday that European Union regulators are recommending approval for its kidney cancer drug Inlyta. A European Union advisory committee recommended that Inlyta be approved as a treatment for advanced renal cell carcinoma in ... Pfizer Kidney Cancer Drug Nears Approval In Europe |
Vertex's cystic fibrosis treatment wins EU regulator's backing - Boston.com
 Proactive Investors USA & Canada | Vertex's cystic fibrosis treatment wins EU regulator's backing Boston.com By Bloomberg News and Globe Staff Vertex Pharmaceuticals Inc.'s Kalydeco, the first medicine to attack the underlying cause of cystic fibrosis, won the backing of the European Union's drug regulator. Kalydeco should be approved by the European ... Vertex Receives European CHMP Positive Opinion for KALYDECO(TM) (ivacaftor ... |
MARKET COMMENT: Europe Stocks End Week Higher After Choppy Session - Wall Street Journal
MARKET COMMENT: Europe Stocks End Week Higher After Choppy Session Wall Street Journal Drug makers were among top gainers on Friday. Novo Nordisk AS added 1.8% as European regulators adopted a positive opinion on the firm's treatment for a rare bleeding disorder. The pan-European index traded in negative territory for most of the ... |
Vertex finds key support for cystic fibrosis drug in Europe - FierceBiotech
Proactive Investors USA & Canada | Vertex finds key support for cystic fibrosis drug in Europe FierceBiotech Vertex ($VRTX) has taken another step toward building a global franchise for treating cystic fibrosis. European regulatory advisers backed approval of the trailblazing drug Kalydeco for a subset of patients with the genetic disorder, paving the way for ... Vertex Pharma receives European recommendation for approval of cystic fibrosis ... |
Sanofi's cholesterol drug reports positive test results - Chicago Tribune
 Updated News | Sanofi's cholesterol drug reports positive test results Chicago Tribune The treatment, a monoclonal antibody that works by blocking a protein called PCSK9 which preserves high bad cholesterol levels in the bloodstream, is a component of a new type of drug that could become effective in preventing heart attack and stroke. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for ... Positive Phase 2 Results For Lipid-Lowering PCSK9 Antibody |
Gaithersburg drug-maker signs deal for European market - Gazette.Net: Maryland Community News Online
Gaithersburg drug-maker signs deal for European market Gazette.Net: Maryland Community News Online The drug is being studied as an antidote for overexposure to the chemotherapy drug 5-fluorouracil due to dosing errors or from impaired clearance of it from the body, according to a Wellstat statement. 5-fluorouracil has been used for decades to treat ... |
ChemoCentryx Presents Data on CCX168, an Orally Administered Small Molecule ... - MarketWatch (press release)
ChemoCentryx Presents Data on CCX168, an Orally Administered Small Molecule ... MarketWatch (press release) CCX168 is currently in a multinational, randomized, double-blind, placebo-controlled Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis, an inflammation of small blood vessels in the ... |
Vertex gets European committee nod - Mass High Tech
 Mass High Tech | Vertex gets European committee nod Mass High Tech The data may lead to greatly increased numbers of CF patients who could be treated with its approved drug Kalydeco, the company said at the time. Approval of the second CF drug candidate, VX-809, would position Vertex as a leader in the treatment of ... |
3 Reasons To Buy Onyx Pharmaceuticals - Seeking Alpha
3 Reasons To Buy Onyx Pharmaceuticals Seeking Alpha The company's first commercially available product, Nexavar, is approved by the United States Food and Drug Administration, or FDA, for the treatment of patients with unresectable liver cancer and advanced kidney cancer. Onyx Pharmaceuticals and Bayer ... |
FDA Advisory Committee Finds Data Support Effectiveness of Tafamidis Meglumine ... - MarketWatch (press release)
 Updated News | FDA Advisory Committee Finds Data Support Effectiveness of Tafamidis Meglumine ... MarketWatch (press release) This recommendation will be taken into consideration by the FDA when making its decision on Pfizer's New Drug Application (NDA) for tafamidis as a treatment for TTR-FAP, a rare and fatal neurodegenerative disease. "TTR-FAP is an irreversible and ... FDA advisory panel gives mixed views on Pfizer's tafamidis FDA staff not impressed with Pfizer rare disease drug tafamidis |